SK Life Science Labs
Christine Stuhlmiller is an accomplished executive with extensive experience in program management within the life sciences sector, currently serving as Vice President of Program Management at SK Life Science Labs since June 2021. Prior roles include Executive Director of GPS Program Management at Bristol Myers Squibb and various senior leadership positions at Celgene, focusing on global project leadership. Christine began their career in finance and operations management, holding roles at the University of Medicine & Dentistry of New Jersey, Oxford Financial Group, and Forum Corporation. Christine holds an MBA in Finance and Marketing from the Weatherhead School of Management at Case Western Reserve University and a BS in Business Management from Cornell University.
This person is not in any teams
SK Life Science Labs
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, is a U.S. biotech company focused on the discovery of transformative medicines through targeted protein degradation (TPD). We discover and develop therapies through precise degradation of disease-causing proteins. Our team takes a target-centric approach through AI enabled target identification. Our core TPD platform, built upon a strong TPD knowledge base, novel E3 ligands & linkers, and machine-learning based ternary complex modeling, is further complemented by a proprietary MOPED™ molecular glue platform. SK Life Science Labs integrates innovative platforms with deep drug-hunting expertise to defeat disease and improve patients’ lives. View our community guidelines here: http://bit.ly/3REsFKU